Kevin Ali is the CEO and Board member of Organon, with the vision of creating a better and healthier every day for every woman around the world. Kevin led the formation of Organon in 2021 to address the significant healthcare issues that women face and deliver impactful solutions all over the world. Kevin has more than three decades of healthcare and commercialization experience from Merck, where he held a number of leadership roles, including President of Merck’s international business, responsible for commercial markets outside the U.S. which account for 96% of the world’s population and over half of Merck’s pharmaceutical revenues. Under Kevin’s leadership, the business was a significant driver of Merck’s growth. Previously, Kevin served as President of the emerging markets region where he transformed the performance of many countries for sustained growth and strength. Earlier in his career at Merck, Kevin was the Managing Director of Germany and Turkey and also led key therapeutic franchises. Kevin holds an M.B.A. from Santa Clara University and a Bachelor of Arts from the University of California, Berkeley.